Literature DB >> 19896088

Impact of declining fertility rates in Canada on donor options in blood and marrow transplantation.

David S Allan1, Sarah Takach, Susan Smith, Mindy Goldman.   

Abstract

An HLA-matched sibling remains the optimal donor for most patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Marked declines in total fertility rates in Canada over the past 50 years will lead to increasing numbers of patients without sibling donors well into the future. We retrieved transplantation data from a Canadian center and the Canadian Blood and Marrow Transplant Group and total fertility data from the United Nations Department of Economic and Social Affairs. The mean age of adults with acute myelogenous leukemia (AML), who underwent transplantation at The Ottawa Hospital between 1995 and 2004, was 41 +/- 12 years (n = 87). The chance of finding 1 or more HLA-matched sibling donors for a patient with AML treated in 2002 is reflected by the total fertility rate in 1961 (average birth year for patients and sibling donors). The sibling rate for 1961 is the total fertility rate-1.0, or 2.68. The chance of having 1 or more HLA-matched sibling is 53.7% (1-chances of no matched sibling, or 1 - 0.75(2.68)). In 2009, the chance of identifying a matched sibling is only 37.1%, because of declining total fertility rates. Following this trend, this chance will be 24.6% in 2014 and 16.6% in 2024. Greater reliance on alternative donors, such as umbilical cord blood (UCB) and HLA-mismatched donors, can be anticipated. The issue of declining fertility rates appears to be regional, and the impact on transplantation will be more pronounced in Canada than in other developed nations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19896088     DOI: 10.1016/j.bbmt.2009.07.007

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  5 in total

1.  Chances of finding a matched parent-child in hematopoietic stem cell transplantation in Saudi Arabia.

Authors:  Ali H Hajeer; Manal Algattan; Aisha Anizi; Ahmed S Alaskar; Mohammad S Jarrar
Journal:  Am J Blood Res       Date:  2012-10-05

Review 2.  Advances in haplo-identical stem cell transplantation in adults with high-risk hematological malignancies.

Authors:  Michael J Ricci; Jeffrey A Medin; Ronan S Foley
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

3.  Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.

Authors:  Sameh Gaballa; Isabell Ge; Riad El Fakih; Jonathan E Brammer; Piyanuch Kongtim; Ciprian Tomuleasa; Sa A Wang; Dean Lee; Demetrios Petropoulos; Kai Cao; Gabriela Rondon; Julianne Chen; Aimee Hammerstrom; Lindsey Lombardi; Gheath Alatrash; Martin Korbling; Betul Oran; Partow Kebriaei; Sairah Ahmed; Nina Shah; Katayoun Rezvani; David Marin; Qaiser Bashir; Amin Alousi; Yago Nieto; Muzaffar Qazilbash; Chitra Hosing; Uday Popat; Elizabeth J Shpall; Issa Khouri; Richard E Champlin; Stefan O Ciurea
Journal:  Cancer       Date:  2016-07-12       Impact factor: 6.860

4.  Modelling improvements in cell yield of banked umbilical cord blood and the impact on availability of donor units for transplantation into adults.

Authors:  Natasha Kekre; Jennifer Philippe; Ranjeeta Mallick; Susan Smith; David Allan
Journal:  Stem Cells Int       Date:  2013-02-20       Impact factor: 5.443

5.  [The family and clinical analysis of matched parent-child in hematopoietic stem cell transplantation].

Authors:  Y H Fan; J Chen; D P Wu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-05-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.